Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
Saved in:
| Title: | Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study. |
|---|---|
| Authors: | Knikman JE; Div. of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Dept. of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de With M; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands; Dept. of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Heersche N; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands; Dept. of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Lopez-Yurda M; Biometrics Dept., The Netherlands Cancer Institute, Amsterdam, the Netherlands., Baars A; Dept. of Medical Oncology, Hospital Gelderse Vallei, Ede, the Netherlands., Creemers GJ; Dept. of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Droogendijk HJ; Dept. of Internal Medicine, Bravis Hospital, Roosendaal, the Netherlands., Fiets E; Dept. of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands., Imholz ALT; Dept. of Internal Medicine, Deventer Hospital, Deventer, the Netherlands., Iersel LV; Dept. of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, the Netherlands., Mandigers CMPW; Dept. of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., van de Vendel AJ; Dept. of Medical Oncology, Hospital Gelderse Vallei, Ede, the Netherlands., Jeurissen FJF; Dept. of Internal Medicine, Haaglanden Medical Centre, The Hague, the Netherlands., Nieboer P; Dept. of Internal Medicine, Wilhelmina Hospital Assen, Assen, the Netherlands., Deenen MJ; Dept. of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands; Dept. of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands., van de Poel MHW; Dept. of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Wymenga MNM; Dept. of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands., van Schaik RHN; Dept. of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., van den Bosch BJC; Dept. Of Clinical Genetics, Maastricht University Medical Centre, Maastricht, the Netherlands., Hoop EO; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands., Rosing H; Dept. of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Swen JJ; Dept. of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands., Gelderblom H; Dept. of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Schellens JHM; Dept. of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Beijnen JH; Dept. of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Div. of Pharmacoepidemiology and Clinical Pharmacology, Dept. of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Mathijssen RHJ; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands., Guchelaar HJ; Dept. of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands., Cats A; Dept. of Gastrointestinal Oncology, Div. of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: a.cats@nki.nl. |
| Source: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Jun 25; Vol. 224, pp. 115483. Date of Electronic Publication: 2025 Apr 30. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
